Pharma firms use Indian women as 'fodder' for trials

[Guest guest]

http://www.keralanext.com/news/index.asp?id=26243

 

India News: Pharma firms use Indian women as 'fodder' for trials

11-February-2004

 

New Delhi, Indian activists are campaigning against rising incidence of

" unethical and exploitative " clinical trials by pharma companies, alleging they

are using " poor Indians as guinea pigs " , reports OneWorld. Prompted by the trial

of 790 women in West Bengal, the All India Democratic Women's Association

(AIDWA) has written to Health Minister Sushma Swaraj expressing their concern.

" We are planning to meet the drug controller to press our demand for stricter

regulations on such trials, " said AIDWA general secretary Brinda Karat. " No one

seems to know what the rules and regulations are. But we can't have a

free-for-all, " she said.

 

The letter follows recent reports that the antibiotic Erythromycin was placed in

the wombs of 790 women to test the drug as a contraceptive. The study found the

antibiotic had a failure rate of up to 35 percent after a year.

The trials, conducted between August 1999 and October 2002, became public after

a paper was published last month in the international journal Contraception.

" It is no coincidence that though all the big pharma companies are based in the

US or Europe, their major tests are conducted on poor people in Third World

countries, " says the letter to the minister.

" They believe that in countries like India they can exploit the vulnerability

caused by unemployment and poverty to induce people to participate in clinical

trials through material incentives, " it says.

 

 

 

 

 

 

 

 

 

 

NEWS/ INFO• Kerala • India• World• Sports• Business• Technology• Health• NRI•

Politics• Election 2004• Bollywood• Malayalam Movie

 

 

 

 

•

 

•

 

•

 

•

 

•

 

•

 

 

 

 

 

 

 

 

The West Bengal trial was conducted by a doctor who stirred a furore when he

tested the anti-malarial drug Quinacrine as a contraceptive for women in India

in the late 1990s.

In 1998, the Indian drug control body banned its use for female sterilisation

after a sustained campaign by women activists, who said more than 30,000 women

in India had been sterilised with Quinacrine over five years without permission

from the health authorities.

As in the case of Quinacrine, the Erythromycin trial sought to check the drug's

efficacy as a contraceptive by blocking a woman's fallopian tubes. The tablets

were placed in the fundus, or the upper part of the uterine cavity.

Reports from West Bengal said the women were divided into two groups.

 

 

Each member of the first group was given a 500 mg tablet, while women in the

second group received 10 50 mg tablets.

A year later, 35 percent of the women in the first group and 28 percent in the

second group had become pregnant.

The doctors did not take permission from the Indian authorities for the trials

despite the fact that doctors in the US have conducted only animal studies in

this field so far -- on rats.

" This points to an extreme laxity in regulations on trials in India, " said Amit

Sengupta of the Delhi Science Forum, a New Delhi-based organisation researching

drugs and health policy.

 

 

" It seems that anybody and everybody can conduct a trial in India, " he said.

In contrast, there are stringent norms for conducting human trials in developed

countries.

AIDWA states that according to pharmaceutical industry estimates, the clinical

studies market in India could multiply from the present $70 million to $300-500

million or even as much as a billion dollars within a decade.

" Poverty forces cruel strategies for survival on the poor, including offering

themselves as fodder for trials for drugs which when finally produced will be of

little use to them or their children because the prices will be far beyond their

reach, " says AIDWA.

 

 

" In any case, no government with even a minimum moral concern for the health

rights of poor Indians can allow them to become guinea pigs for multinational

companies, " it states.

Sengupta pointed out that such trials were being conducted in India because it

had a technical manpower that is cheaper than in Western nations, a research

base as well as existing health infrastructure.

For its part, the government is reported to have prepared a draft law, which

will make any violation of guidelines for biomedical research on human beings a

severely punishable criminal act.

" The draft is ready and is likely to be introduced in parliament this year, "

Indian health secretary J.V.R. Prasada Rao said.

But AIDWA, which is still awaiting a reply from the health minister, remains

sceptical about how seriously the government will pursue the issue.

 

Indo-Asian News Service

 

 

 

 

 

 

 

Finance: Get your refund fast by filing online